Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Gynecologic Cancers
SGO 2024
Questions discussed in this category
What are your top takeaways from SGO 2024?
2 Answers available
19358
Papers discussed in this category
Lancet (London, England), 2024 Mar 20
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
N Engl J Med, 2023 Mar 27
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Lancet (London, England), 2023 Dec 01
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Related Topics in Gynecologic Cancers
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers
Melanoma/Skin Cancer
